· Published by Health Canada · Official notice
Notice about Health Canada advisories
November 23, 2006
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Surgery, Emergency Medicine, Pharmacy, Pediatrics, Anesthesia, Internal Medicine, Nursing, Dentistry, Otolaryngology, Gastroenterology and other involved professional staff and post this notice in your institution.
Subject: Association of Benzocaine Sprays with Methemoglobinemia
Benzocaine sprays are indicated for use during surgical, dental and other medical procedures to topically anesthetize mucous membranes and help obtund the pharyngeal and tracheal reflexes.
Methemoglobinemia (MHb) is an uncommon adverse reaction known to be associated with benzocaine. MHb results in an impaired ability of red blood cells to bind and carry oxygen and may lead to cyanosis, weakness and coma. Benzocaine products are available in many different topical forms, but almost all reported cases of benzocaine-induced MHb have been associated with higher concentration (14-20% benzocaine) spray products used in the mouth and on other mucous membranes.
Although this potentially life-threatening reaction is well established, cases continue to be reported to Health Canada, and the number of cases reported in the medical literature also appears to be increasing. Accordingly, Health Canada reminds health care professionals that benzocaine sprays must be used judiciously to minimize the risk of acquired MHb.
Recommendations:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of MHb or other serious or unexpected adverse reactions in patients receiving benzocaine should be reported to the manufacturer or to Health Canada at the following address:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
References:
Moore TJ, Walsh CS, Cohen MR. Reported Adverse Event Cases of Methemoglobin Associated With Benzocaine Products. Arch Intern Med 2004;164:1192-1196.
Armstrong C, Burak KW, Beck PL. Benzocaine-induced methemoglobinemia: A condition of which all endoscopists should be aware. Can J Gastroenterol 2004;18(10):625-629.